Can-Fite BioPharma (CANF) announced an update related to the intellectual property, IP, status of its lead drug candidate Namodenoson, currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis, MASH, advanced liver cancer and pancreatic cancer. In all clinical studies that have been conducted, Namodenoson had a very favorable safety profile when administered orally.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Secures Lucrative Deal with Vetbiolix
- Can-Fite BioPharma reports results from osteoarthritis clinical study in dogs
- Can-Fite’s Namodenoson Gains FDA Orphan Status
- Can-Fite BioPharma announces FDA granted ODD for Namodenoson
- Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status